Acute Reactions to Mega Ascorbic Acid Therapy in Malignant Disease

Campbell, Allan; Jack, Thomas

doi:10.1177/003693307902400210

Cited by 17 publications

(17 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ascorbate (n 5 4,380 participants) (Table 3). One study was a randomized controlled trial [45], three were nonrandomized phase I or II studies [48][49][50], four were observational studies [10,11,46,47], and four were case reports [9,23,51,52]. The median year of publication was 1991 (range, 1974-2012).…”

Section: Characteristicsmentioning

confidence: 99%

“…No tumor response was seen.The four other studies using oral and i.v. ascorbate were case reports of a variety of malignancies [9,22,23,51,52]. Patients were treated both with ascorbate alone and in combination with chemotherapy.…”

Section: Cmementioning

confidence: 99%

“…A variety of outcomes were reported. Toxicity was also reported, including "dangerous" toxicity in the paper by Campbell and Jack [51]; no grading criteria were used to define this toxicity.…”

Section: Cmementioning

confidence: 99%

See 2 more Smart Citations

Is There a Role for Oral or Intravenous Ascorbate (Vitamin C) in Treating Patients With Cancer? A Systematic Review

et al. 2015

View full text Add to dashboard Cite

Background. Many cancer patients receive supplemental ascorbate (vitamin C) in the belief that it synergizes the anticancer effects of chemotherapy and reduces its toxicity. Methods. A systematic review was performed to evaluate the antitumor effects and toxicity of ascorbate treatment. Medline (1946 to March 2014), EMBASE (1947 to March 2014), and the Cochrane central register (1993 to March 2014) were searched for randomized and observational studies. Results. Of 696 identified records, 61 full‐text articles were screened and 34 were included. In total, 5 randomized controlled trials (RCTs) (n = 322), 12 phase I/II trials (n = 287), 6 observational studies (n = 7,599), and 11 case reports (n = 267) were identified. Because of study heterogeneity, no meta‐analyses were performed. No RCTs reported any statistically significant improvements in overall or progression‐free survival or reduced toxicity with ascorbate relative to control arm. Evidence for ascorbate's antitumor effects was limited to case reports and observational and uncontrolled studies. Conclusion. There is no high‐quality evidence to suggest that ascorbate supplementation in cancer patients either enhances the antitumor effects of chemotherapy or reduces its toxicity. Given the high financial and time costs to patients of this treatment, high‐quality placebo‐controlled trials are needed.

show abstract

Section: Characteristicsmentioning

confidence: 99%

Section: Cmementioning

confidence: 99%

See 1 more Smart Citation

Is There a Role for Oral or Intravenous Ascorbate (Vitamin C) in Treating Patients With Cancer? A Systematic Review

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Another valid concern when applying ascorbate intravenously is a rapid tumor hemorrhage and necrosis. 143 However, in the 28 years of administering intravenous vitamin C at the Center for the Improvement of…”

Section: Safety and Toxicity Considerations Of High Doses Of Aamentioning

confidence: 99%

Orthomolecular Oncology Review: Ascorbic Acid and Cancer 25 Years Later

et al. 2005

View full text Add to dashboard Cite

The effect of ascorbic acid on cancer has been a subject of great controversy. This is a follow-up review of the 1979 article by Cameron, Pauling, and Leibovitz published in Cancer Research. In this updated version, the authors address general aspects of ascorbic acid and cancer that have been presented before, while reviewing, analyzing, and updating new existing literature on the subject. In addition, they present and discuss their own mechanistic hypothesis on the effect of ascorbic acid on the cancer cell. The objective of this review is to provide an updated scientific basis for the use of ascorbic acid, especially intravenously as adjuvant treatment in pharmacological nutritional oncology.

show abstract

“…1,50 Although tumour hemorrhage suggests an anticancer potential for ascorbate, there is the potential for risk to some patients.…”

mentioning

confidence: 99%